Meta Information
ID:retatrutide
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Interactions
Target id:
/class/antidiabetic-medications
Target name:
Other Diabetes Medications (especially Insulin or Sulfonylureas)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Retatrutide potently lowers blood glucose, and combining it with other glucose-lowering drugs like insulin or sulfonylureas significantly increases the risk of severe hypoglycemia (dangerously low blood sugar).
Actionable advice:
Your doctor must review and likely reduce the dosage of your other diabetes medications when starting Retatrutide.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.3 Hypoglycemia [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Source url:
Exact phrase from label:
There were no reports of severe hypoglycaemia and no deaths during the study.
Label source:
PubMed: Rosenstock J et al., Lancet (2023) - retatrutide phase 2 type 2 diabetes trial; severe hypoglycemia not seen with retatrutide (with metformin) alone (PMID 37385280)
Action type:
informational_none
Target id:
/class/glp-1-receptor-agonists
Target name:
Other GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Using Retatrutide with other GLP-1 agonists is duplicative therapy, as they share a mechanism of action. This combination has not been studied and would significantly increase the risk and severity of gastrointestinal side effects.
Actionable advice:
Retatrutide should not be used concurrently with any other GLP-1 receptor agonist medication.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Pharmacologic class inference (no primary source located)
Exact phrase from label:
Class inference: retatrutide is a GLP-1 (plus GIP and glucagon) receptor agonist; co-administering another GLP-1 receptor agonist is duplicative therapy with additive GI effects and no incremental benefit. No combination study exists.
Label source:
Class inference
Action type:
avoid
Target id:
/intervention/tirzepatide
Target name:
Tirzepatide
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Using Retatrutide with Tirzepatide is duplicative therapy, as they share both the GLP-1 and GIP receptor agonist mechanisms. This combination would lead to an excessive and unstudied level of incretin stimulation, increasing side effect risks.
Actionable advice:
Retatrutide and Tirzepatide should not be used at the same time.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Pharmacologic class inference (no primary source located)
Exact phrase from label:
Class inference: retatrutide (GLP-1/GIP/glucagon) and tirzepatide (GLP-1/GIP) overlap on the GLP-1 and GIP receptors; concurrent use is duplicative and would produce additive, unstudied incretin stimulation. No combination study exists.
Label source:
Class inference
Action type:
avoid
Target id:
/condition/medullary-thyroid-carcinoma-history
Target name:
Personal or Family History of Medullary Thyroid Carcinoma (MTC) or MEN 2
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
In animal studies, drugs in this class caused thyroid C-cell tumors. It is unknown if this risk applies to humans, but as a precaution, it is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Actionable advice:
This should be strictly avoided if a personal or family history of MTC or MEN 2 is present.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.1 / 4 Contraindications (Boxed Warning: Risk of Thyroid C-Cell Tumors) [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
avoid
Target id:
/condition/gastroparesis
Target name:
Gastroparesis (Delayed Gastric Emptying)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Retatrutide's mechanism involves slowing down stomach emptying. In individuals with pre-existing gastroparesis, this effect would worsen the condition, potentially leading to severe nausea, vomiting, and malnutrition.
Actionable advice:
This should be strictly avoided with a diagnosis of moderate to severe gastroparesis.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time.
Label source:
FDA label: MOUNJARO (tirzepatide), 12.2 Pharmacodynamics [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Source url:
Exact phrase from label:
The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.
Label source:
PubMed: Jastreboff AM et al., N Engl J Med (2023) - retatrutide phase 2 obesity trial (PMID 37366315)
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
There is no data on the use of Retatrutide in pregnant women, and significant weight loss is not recommended during pregnancy. Potential fetal harm cannot be ruled out.
Actionable advice:
This should be strictly avoided during pregnancy or when planning to become pregnant.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. ... Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy.
Label source:
FDA label: MOUNJARO (tirzepatide), 8.1 Pregnancy [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known whether Retatrutide passes into human breast milk. Due to the potential for adverse effects in a nursing infant, its use is not recommended.
Actionable advice:
It should be avoided completely while breastfeeding.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
There are no available data on the effects of tirzepatide on the breastfed infant or on milk production.
Label source:
FDA label: MOUNJARO (tirzepatide), 8.2 Lactation [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
avoid
Target id:
/procedure/surgery-anesthesia
Target name:
Surgery with General Anesthesia
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
168
Hours after target:
null
Description:
Retatrutide delays gastric emptying, which increases the risk of regurgitation and aspiration of stomach contents into the lungs during anesthesia. This can cause serious complications.
Actionable advice:
A surgeon should be informed about Retatrutide use; it should be stopped at least one week before elective surgery.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
MOUNJARO delays gastric emptying [see Clinical Pharmacology (12.2)].
Label source:
FDA label: MOUNJARO (tirzepatide), 5.6 (Pulmonary aspiration / delayed gastric emptying) [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
separate
Target id:
/class/oral-medications-general
Target name:
All Orally Administered Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
4
Description:
By delaying gastric emptying, Retatrutide can slow down the absorption of any medication taken by mouth, potentially reducing its peak concentration and effectiveness.
Actionable advice:
Oral medications are best taken at least 1 hour before or 4+ hours after the largest meal of the day to minimize absorption impact.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
MOUNJARO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.
Label source:
FDA label: MOUNJARO (tirzepatide), 7.1 Drug Interactions [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
separate
Target id:
/class/estrogens
Target name:
Oral Contraceptives
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Delayed gastric emptying caused by Retatrutide can reduce the absorption rate of oral contraceptives, potentially compromising their effectiveness.
Actionable advice:
It is important to talk to a doctor about using a non-oral backup method of contraception, especially for the first month of use.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. ... Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO.
Label source:
FDA label: MOUNJARO (tirzepatide), 8.3 / 7.2 [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Source url:
Exact phrase from label:
mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in tmax of 2.5 to 4.5 hours was observed.
Label source:
FDA label: MOUNJARO (tirzepatide), 12.3 (single 5 mg dose + combined oral contraceptive) [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
informational_none
Target id:
/condition/history-of-pancreatitis
Target name:
History of Pancreatitis
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Medications in this class have been associated with an increased risk of acute pancreatitis. The risk may be higher in individuals with a prior history of the condition.
Actionable advice:
This is best used with caution, and it is important to promptly report any symptoms of severe, persistent abdominal pain to a doctor.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.2 Acute Pancreatitis [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
monitor
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Severe gastrointestinal side effects like vomiting or diarrhea can lead to dehydration, which can cause or worsen kidney problems. The drug itself is not directly toxic to the kidneys.
Actionable advice:
Excellent hydration is best maintained, especially during dose escalation, and any decrease in urination is worth reporting.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
There have been postmarketing reports of acute kidney injury ... The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.5 Acute Kidney Injury Due to Volume Depletion [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
monitor
Target id:
/condition/gallbladder-disease
Target name:
Gallbladder Disease
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Rapid weight loss, a common effect of Retatrutide, is a known risk factor for developing gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).
Actionable advice:
Any new symptoms of sharp pain in the upper right abdomen, nausea, or fever are worth reporting to a doctor.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.8 Acute Gallbladder Disease [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Source url:
Exact phrase from label:
At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
Label source:
PubMed: Jastreboff AM et al., N Engl J Med (2023) - retatrutide produced rapid, large weight loss (PMID 37366315)
Action type:
monitor
Target id:
/dietary/meal
Target name:
Large, High-Fat, or High-Sugar Meals
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Because Retatrutide slows stomach emptying, consuming large or rich meals can overwhelm the digestive system, significantly worsening side effects like nausea, bloating, and reflux.
Actionable advice:
Eat smaller, more frequent, lower-fat meals to minimize gastrointestinal discomfort.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Pharmacologic class inference (no primary source located)
Exact phrase from label:
Class inference: because incretin agonists delay gastric emptying and commonly cause nausea/bloating (labeled GI adverse reactions), large, high-fat or high-sugar meals predictably worsen these GI symptoms; smaller, lower-fat meals are standard tolerability advice. Practical recommendation, not a discrete labeled interaction.
Label source:
Class inference
Source url:
Exact phrase from label:
Mild-to-moderate gastrointestinal adverse events, including nausea, diarrhoea, vomiting, and constipation, were reported in 67 (35%) of 190 participants in the retatrutide groups
Label source:
PubMed: Rosenstock J et al., Lancet (2023) - retatrutide GI adverse events (PMID 37385280)
Action type:
informational_none
Target id:
/dietary/alcohol-acute
Target name:
Alcohol (Acute Consumption)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Alcohol can independently lower blood sugar, and when combined with Retatrutide, it can increase the risk of hypoglycemia. It can also irritate the stomach, exacerbating GI side effects.
Actionable advice:
Alcohol consumption is best limited, and drinking on an empty stomach is best avoided to reduce risks.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Pharmacologic class inference (no primary source located)
Exact phrase from label:
Class inference: alcohol can independently cause hypoglycemia and gastric irritation, which are additive with retatrutide's glucose-lowering and GI effects. General pharmacologic reasoning; no retatrutide-specific study.
Label source:
Class inference
Action type:
separate
Target id:
/dietary/water
Target name:
Fluid Intake
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Adequate hydration is crucial to counteract potential fluid loss from gastrointestinal side effects (nausea, vomiting, diarrhea) and to protect kidney function.
Actionable advice:
It is a good idea to drink plenty of water and electrolyte-containing fluids throughout the day.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Pharmacologic class inference (no primary source located)
Exact phrase from label:
Class inference (corollary of the labeled volume-depletion risk): the tirzepatide label ties GI adverse reactions (nausea, vomiting, diarrhea) leading to dehydration to acute kidney injury; maintaining adequate fluid/electrolyte intake is the direct preventive measure, especially during dose escalation.
Label source:
Class inference
Action type:
informational_none
Target id:
/condition/diabetic-retinopathy
Target name:
Diabetic Retinopathy
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Rapid improvements in blood sugar control have been associated with a temporary worsening of diabetic retinopathy in some individuals. This is a known effect of potent glucose-lowering therapies.
Actionable advice:
Regular eye exams may help, especially when starting or significantly changing diabetes treatment.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. ... Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.7 Diabetic Retinopathy Complications [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
informational_none
Target id:
/biomarker/resting-heart-rate
Target name:
Resting Heart Rate
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Retatrutide and other GLP-1 agonists can cause a small, dose-dependent increase in resting heart rate. The clinical significance of this is generally considered low for most people.
Actionable advice:
A small increase in resting heart rate may occur; reporting palpitations or a persistently high rate to a doctor is worthwhile.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
treatment of adults with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. ... The clinical relevance of heart rate increases is uncertain.
Label source:
FDA label: MOUNJARO (tirzepatide), 6.1 Adverse Reactions [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Source url:
Exact phrase from label:
The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.
Label source:
PubMed: Jastreboff AM et al., N Engl J Med (2023) - retatrutide phase 2 obesity trial (PMID 37366315)
Action type:
monitor
Target id:
/biomarker/amylase-lipase
Target name:
Amylase and Lipase Levels
Severity:
minor
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
Asymptomatic elevations in pancreatic enzymes (amylase and lipase) can occur with this class of medication. This is not necessarily indicative of pancreatitis without corresponding symptoms.
Actionable advice:
Minor elevations on lab tests are generally not a cause for alarm, but any severe abdominal pain is worth reporting immediately.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Pharmacologic class inference (no primary source located)
Exact phrase from label:
Class inference: asymptomatic increases in pancreatic enzymes (amylase and lipase) are a recognized, labeled adverse-reaction observation across the GLP-1/incretin class and are not by themselves diagnostic of pancreatitis. Retatrutide-specific enzyme data not separately quoted here.
Label source:
Class inference
Action type:
monitor
Target id:
/biomarker/calcitonin
Target name:
Serum Calcitonin
Severity:
minor
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
Due to the theoretical risk of thyroid C-cell effects, serum calcitonin (a biomarker for MTC) may be monitored. The relevance of small changes during treatment is uncertain.
Actionable advice:
If your doctor monitors calcitonin levels, discuss the results in the context of your overall health.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO.
Label source:
FDA label: MOUNJARO (tirzepatide), 5.1 Risk of Thyroid C-Cell Tumors [class-derived: retatrutide shares the GLP-1/GIP incretin mechanism]
Action type:
monitor